marijuana-related activities are expected to: Describe the nature of the public company’s involvement in the U.S. marijuana industry and include the disclosures indicated based on the nature of such involvement as either direct, indirect or ancillary (as discussed below); Explain that marijuana remains illegal under U.S. federal law and that the approach to enforcement by the U.S. federal government is subject to change, as well as a discussion of resultant risks of such change including the potential for adverse enforcement action; State whether and how the public company’s marijuana-related activities are conducted in a manner consistent with any U.S. federal enforcement priorities; and Given the illegality of marijuana under U.S. federal law, discuss the public company’s ability to access both public and private capital markets and indicate what financing options are available to support continuing operations. For public companies directly Green Rush engaged in the cultivation or distribution of marijuana in the U.S. in accordance with a state license, the following disclosure is required: An outline of the regulations for the U.S. state(s) in which the public company operates and confirm how the public company complies with applicable licensing requirements and the applicable regulatory framework; A discussion of the public company’s program for monitoring compliance with U.S. state law on an ongoing basis and its internal compliance mechanisms; and Disclosure of any material non-compliance, as well as material citations or notices of violation. For public companies with indirect involvement in cultivation or distribution of marijuana by way of a non-controlling investment in an entity who is directly involved in the U.S.
To read more visit https://www.lexology.com/library/detail.aspx?g=2e0af220-ae61-4be9-8f4b-55ee4e14b12b
The credit rating agency estimates state and local taxes on marijuana, which will become Marijuana Stocks legal in California on Jan. 1., could be as high as 45 percent in some cases. It would trail only Washington state, which levies a 50 percent tax on marijuana. “The existing black market for cannabis may prove a formidable competitor to legal markets if new taxes lead to higher prices than available from illicit sources,” the report says. Recreational marijuana will be taxed on both the state and local level, contributing to the potential for high rates. California will impose a 15 percent excise tax, as well as cultivation taxes. Municipalities will also levy sales tax and a business tax, which could be anywhere from 1 to 20 percent, on gross receipts. Business taxes on recreational marijuana have been approved by voters in 61 California cities and counties, according to the report. These high tax rates have the potential to drive customers toward the black market. The state is the nation’s epicenter of marijuana growing and has long provided black market pot. The report states that Colorado, Oregon and Washington all reduced tax rates after the commencement of legalization to shift customers back toward the legal market. California will implement a statewide framework for marijuana legalization, but each municipality must decide whether it wants to house marijuana businesses and, if so, map out its own regulations and tax structure.
To read more visit https://www.washingtonpost.com/news/post-nation/wp/2017/10/30/high-taxes-could-drive-up-marijuana-prices-and-bolster-the-black-market-in-california-analysis-says/
New Hampshire Lawmakers on Marijuana Panel Begin Examination of Legalization The commission tasked with exploring legalization in the state will issue its final report next November. A commission tasked with exploring marijuana legalization in New Hampshire held its first meeting Tuesday, setting off a yearlong examination process ahead of its final report next November. Created by House Bill 215, the commission is charged with looking at what might happen if the state legalized marijuana, regulating and taxing it like alcohol, along the model of other states. STATE BY STATE: New Hampshire Cannabis News The goal is broad. Among the topics to be considered, according to the commission, are how legalization might affect the opioid crisis, crime rates, children’s health, DUI accidents, taxation policies and New Hampshire’s brand. “To me, in simple form, Green Rush I think it’s our job to identify the good, the bad and the ugly of legalization,” Rep. Patrick Abrami, the commission’s chairman, said at the meeting Tuesday. The commission will reach out to states that have already undertaken the effort, such as Colorado, which implemented legalization in 2014, and Massachusetts, which will roll out its legalization effort next summer. Members will try to set up video conferences with state officials over Skype, said Abrami, a Stratham Republican.
To read more visit http://www.cannabisbusinesstimes.com/article/new-hampshire-lawmakers-begin-examination-of-legalization/
The number of farms in Mendocino County, where the illicit market thrives, is unknown. Both the California Cannabis Industry Association and the California Growers Association reported ” several dozen ” members that lost their farms in the blazes. It’s too soon to say what percent of grows in California were affected by the fires, though it appears to be a minority. Smoke also blanketed huge swaths of Northern California last week, which presents a more widespread concern for the marijuana industry, according to Nick DiNicola, whose company, DiNicola Insurance Services, brokers insurance for companies in the cannabis space. “A lot of the farms weren’t destroyed but may Medical marijuana stocks not be able to sell their product because of all the pollution that came down from the fires,” DiNicola told Business Insider. Smoke-exposed crops are more vulnerable to disease , which could lead to unhealthy levels of mold, mildew, and fungus. The marijuana might also smell like fire, which causes it to lose value if it’s meant to smell like “lemon haze” or “blueberry kush,” according to the San Francisco Chronicle . Flames surround a marijuana plant as a wildfire burns near Oroville, California, on Saturday, July 8, 2017. Noah Berger/AP Still, the fires reached only a small section of the Emerald Triangle, which also includes Humboldt County and Trinity County. Local dispensaries that source their inventory from the counties affected by the fires are more likely to experience higher prices.
To read more visit http://www.businessinsider.com/marijuana-price-increases-after-santa-rosa-fires-2017-10
Among other responsibilities, Mr. Vleeming was in charge of the division running the corporation’s mission critical IT systems, general IT asset management, as well as development of the corporation’s strategic technology vision to drive competitive differentiation. Prior to Capital Power, Mr. Vleeming was Manager of Systems Development at EPCOR, one of Canada’s top providers of energy and energy-related services and products in Alberta, Ontario, and the United States. Mr Vleeming sits on the Board of Directors of a number of not-for-profit and charitable organizations, including Cybera, which is responsible for overseeing the development of Alberta’s cyber infrastructure, and The Rainbow Society of Alberta, a registered charity dedicated to fulfilling wishes of Alberta children with chronic or life threatening illnesses. Mr. Vleeming holds an Executive MBA from the University of Athabasca, and a Computer Systems Technology Honours Diploma from the Northern Alberta Institute of Technology (NAIT). The newly created position of CIO reflects the degree to which leadership in technology and innovation is part of our DNA, as well as central to our global expansion strategy. With his exceptional track record of identifying technological opportunities and executing technology-driven strategies, we believe Darryl is the right person to help us scale up Aurora’s e-commerce platform, establish systems to manage the vast amount of data we generate, and ensure tight alignment across our domestic and international operations. We are very pleased to have attracted a leader of his calibre, and look forward to his contributions to driving accelerated growth.
To read more visit marijuana href=’https://www.newcannabisventures.com/aurora-cannabis-appoints-darryl-vleeming-chief-information-officer/’ rel=’nofollow’>https://www.newcannabisventures.com/aurora-cannabis-appoints-darryl-vleeming-chief-information-officer/
Chart source: thinkorswim® by TD Ameritrade . Data source: Standard & Poor’s. Not a recommendation. For illustrative purposes only. Past performance does not guarantee future results. Eight states and Washington D.C. have legalized the recreational use of marijuana, and 44 states have laws governing medicinal use. Laws vary from state to state, which adds complexities that can result in companies or individuals violating state production and distribution laws. An even greater source of uncertainty for companies is that all these activities are illegal under federal law because marijuana is still a Schedule I substance under the Controlled Substances Act. The U.S. Drug Enforcement Administration defines Schedule I substances as “drugs with no currently accepted medical use and a high potential for abuse.” How are these companies getting away with it then?
To Medical marijuana stocks read more visit https://www.benzinga.com/general/education/17/05/9539243/investing-in-marijuana-stocks-dont-let-your-money-go-up-in-smoke
What the heck is going on here? More than likely, this move has to do with the anticipation of GW Pharmaceuticals’ filing for a new drug application (NDA) with the Food and Drug Administration (FDA) for Epidiolex very soon. Epidiolex is an oral cannabinoid-based medicine that, in phase 3 clinical trials, generated a statistically significant reduction in seizure frequency for patients with two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. GW Pharmaceuticals’ management team has suggested that investors expect an NDA filing by mid-2017, which would signal it’s due any time now. If Epidiolex gets a green light from the FDA, and it’s fortunate enough to expand its label beyond just the two aforementioned rarer types of epilepsy, it could make a run at perhaps $1 billion in peak annual sales. This is why investors are so bullish regarding GW Pharmaceuticals. Still, we’ll need to see if the FDA grants the company a priority review, which would shorten the NDA review period by four months to a six-month process and get Epidiolex to market quickly. Further, an approval is no guarantee for a cannabinoid-based product. Likewise, with the company’s only Marijuana Stocks other approved product (outside the U.S.), Sativex, failing to garner much in the way of sales, there are concerns about GW Pharmaceuticals’ effectiveness in marketing and pricing Epidiolex, if approved. For the time being, the company’s stock appears priced for perfection. Unlike GW Pharmaceuticals, where hope seems to reign supreme, three press releases over the past couple of weeks have been wholly responsible for Aurora Cannabis’ ( NASDAQOTH:ACBFF ) charge higher. In just two weeks, the Canadian medical-cannabis producer and retailer has seen its share price rocket 29% higher.
To read more visit https://www.fool.com/investing/2017/07/26/the-3-hottest-marijuana-stocks-right-now.aspx
CannabisNewsWire Announces Publication Highlighting Investment Opportunities in Cryptocurrency NEW YORK, NY–(Marketwired – Oct 25, 2017) – CannabisNewsWire (“CNW”), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring SinglePoint, Inc. ( : SING ), a client of CNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, “Bitcoin’s Recent Gains Spell Opportunity for Cryptocurrency Companies,” shines a light on the current demand for alternative investment options. To view the full publication, visit: https://www.cannabisnewswire.com/bitcoins-recent-gains-spell-opportunity-cryptocurrency-companies/ “SinglePoint has entered a period of rapid development aimed at executing on its bitcoin payments solution. The company’s management team noted that a recently announced new round of funding would play a key role in SinglePoint’s efforts to “move very quickly to develop a cryptocurrency solution and continue acquisitions in the cannabis space.” In early August, SinglePoint confirmed ( http://cnw.fm/RPwq4 ) the swiftness of its development efforts by announcing the commencement of development for its in-house solution enabling consumers to ‘obtain bitcoin at any point of sale.’ While this new payment exchange is expected to be particularly Medical marijuana useful to the maturing cannabis sector, its potential applications could extend well beyond the bounds of marijuana. “As SinglePoint noted in a news release, its new product will be ‘a payment service to make instant bitcoin powered purchases possible when all you have is a credit (or debit) card,’ presenting upside for a wide variety of businesses, most notably in high risk markets.” SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.
To read more visit http://www.marketwired.com/press-release/cannabisnewswire-announces-publication-highlighting-investment-opportunities-cryptocurrency-pinksheets-sing-2238295.htm
Two years ago, Arena reported positive phase 1b results involving etrasimod for the treatment Medical marijuana of various autoimmune diseases, including ulcerative colitis, which is currently in phase 2 studies. The early stage study demonstrated up to a 69% dose-dependent lowering in lymphocyte count from baseline, which returned to normal within one week after the conclusion of dosing. The press release suggested that this early data was consistent with the efficacy shown in successful phase 2 and 3 studies involving S1P1 modulators in multiple sclerosis, psoriasis, and ulcerative colitis. In other words, etrasimod, though still in early trials, looks promising. Of course, the real buzz involves APD371 , which is an oral Crohn’s disease pain drug that targets the CB2 receptor of the naturally occurring cannabinoid receptor system in our bodies. Targeting CB2 is a smart move for Arena (and other drugmakers, for that matter) since the CB2 receptor has been shown to provide pain relief without the normal psychoactive effects observed with targeting the CB1 receptor. Its primary goal is to replace opioids, which can be addictive and even deadly. Some 20,000 people in the U.S. died from prescription opioid-related overdoses in 2015, compared to zero marijuana-based overdose deaths. A placebo-controlled phase 1b dose-escalating study involving APD371 appeared safe, with only low-grade adverse events observed. Furthermore, all doses tested, even lower doses, were deemed to be more than enough to stimulate the CB2 receptor and achieve the desired biologic effect. Replacing opioid therapies is a lofty goal, but it’s Arena’s biggest hope.
To read more visit https://www.fool.com/investing/2017/06/23/better-know-a-marijuana-stock-arena-pharmaceutical.aspx
According to both the 2016 Gallup poll and the more recent CBS News poll, an all-time record percentage of respondents — 60% and 61%, respectively — want to see marijuana legalized across the country. If pollsters focus purely on medical cannabis, favorability toward legalization shoots to somewhere in the neighborhood of 90%, depending on the source of the survey. With such growing acceptance of cannabis, marijuana stock investors fully anticipate that recreational and medical sales will continue to thrive. From a sales perspective, a recent Marijuana Business Daily report titled “Marijuana Business Factbook 2017” found that U.S. sales are expected to grow approximately 30% this year to a range of $5.1 billion to $6.1 billion, with legal recreational and medical sales combined reaching a projected $17 billion by 2021. Between 2016 and 2021 we’re looking at 300% sales growth . Investors would struggle to find more consistent growth elsewhere, which is why they’ve flocked to pot stocks. Hot marijuana stocks that are growing like a weed However, over the two-week period between July 7 and July 21, three marijuana stocks have really stood out from the pack for Marijuana Stocks their impressive percentage or market-cap gains. Let’s have a closer look at which companies have truly been “growing like a weed” recently. In spite of no major news events, the mammoth of all marijuana stocks, GW Pharmaceuticals ( NASDAQ:GWPH ), has seen its share price move higher by nearly 13% over a two-week period. On a valuation basis, we’re talking about $325 million being added in just 10 days’ time. What the heck is going on here?
To read more visit https://www.fool.com/investing/2017/07/26/the-3-hottest-marijuana-stocks-right-now.aspx